Johnson & Johnson, Abbott Laboratories, and Becton, Dickinson don't fall as far as other healthcare stocks and bounce back faster during economic downturns.
Healthcare product and device company Abbott Laboratories (NYSE:ABT) announced better-than-expected revenue in Q1 CY2026, with sales up 7.8% year on year to ...
Johnson & Johnson (NYSE: JNJ) delivered a robust first-quarter 2026 earnings report on April 14, 2026, handily beating Wall Street expectations and signaling a successful navigation of the long-feared "Stelara" patent cliff. The healthcare titan reported an adjusted earnings per share (EPS) of $2.70, comfortably ahead of the $2.66
As the sun sets on the era of easy profits from elevated interest rates, the titans of Wall Street are preparing to unveil a new chapter in their growth stories. For the first time in three years, the narrative surrounding the upcoming Q1 2026 earnings for Goldman Sachs (NYSE: GS)
The first quarter of 2026 has concluded with a historic roar, as global Mergers and Acquisitions (M&A) reached a staggering $438 billion in deal value. This surge, a 155% increase over the same period in 2025, signals a definitive return of "animal spirits" to corporate boardrooms. Despite a backdrop
The global financial landscape underwent a seismic shift in the first quarter of 2026, as a "perfect storm" of stabilizing interest rates and technological urgency triggered a historic wave of mergers and acquisitions. Total deal volume for the quarter reached a staggering $1.25 trillion, marking a 26% increase over
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings.
Today marks a definitive turning point for Hologic, Inc. (NASDAQ: HOLX). As the company prepares to finalize its $18.3 billion acquisition by private equity giants Blackstone and TPG, it stands as a testament to the resilience and strategic focus required in the modern medtech landscape. Known globally as a pioneer in women’s health, Hologic has [...]
In a move that cements the "human performance" category as a pillar of the future economy, Whoop has officially closed a massive $575 million Series G funding round, catapulting the wearable technology leader to a $10.1 billion valuation. The round was led by the global alternative asset manager TPG
ST. LOUIS – April 6, 2026 – In a milestone that signals a paradigm shift for cardiac care, Stereotaxis (NYSE American: STXS) has received FDA 510(k) clearance for its Synchrony™ System. The approval marks the official commercial launch of the world’s first integrated "digital cockpit" for robotic electrophysiology (EP), a
